SCHEMBL2516121

SCHEMBL2516121

CC(C)(C)c1ccc(CON)cc1

nearest known ligand 0.63

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 16/20 0.63
AGXT P21549 8/20 0.58
CYP3A4 P08684 2/20 0.52
APP P05067 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4367676 0.81 APP (0.55) APP
SCHEMBL438248 0.80 IDO1 (0.78) IDO1AGXTCYP3A4
SCHEMBL780050 0.79 APP (0.53) APP
SCHEMBL1520538 0.77 IDO1 (1.00) IDO1AGXTCYP3A4
SCHEMBL13359294 0.77 APP (0.56) APP
SCHEMBL1691492 0.77 APP (0.52) APP
SCHEMBL20620504 0.77 IDO1 (0.52) IDO1AGXTCYP3A4
SCHEMBL22275947 0.76 APP (0.82) APP
Hydrochloric Acid SCHEMBL1715250 0.76 IDO1 (1.00) IDO1AGXT
SCHEMBL8251933 0.76 APP (0.50) APP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
CN-1906155-A Novel hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA AS (DK) 2007-01-31 CN claimed
US-9353144-B2 Vascular leakage inhibitor INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2016-05-31 US disclosed
US-9353144-B2 Vascular leakage inhibitor INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) 2016-05-31 US disclosed
US-20140378399-A1 NOVEL VASCULAR LEAKAGEAGE INHIBITOR CURACLE CO., LTD. (KR) 2014-12-25 US disclosed
US-20140378399-A1 NOVEL VASCULAR LEAKAGEAGE INHIBITOR CURACLE CO., LTD. (KR) 2014-12-25 US disclosed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 US disclosed
CN-1906155-B Novel hydroxamic acid ester derivant and pharmaceutical use thereof LEO PHARMA AS 2010-06-23 CN disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US disclosed
CN-1906155-A Novel hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA AS (DK) 2007-01-31 CN disclosed
US-5723450-A Substituted pyridines, their preparation, and their use as pesticides and fungicides HOECHST SCHERING AGREVO GMBH (DE) 1998-03-03 US disclosed
EP-0719256-A1 SUBSTITUTED PYRIDINES, PROCESS FOR PRODUCING THEM AND THEIR USE AS PESTICIDES AND FUNGICIDES Hoechst Schering AgrEvo GmbH (DE) 1996-07-03 EP disclosed
WO-1995007891-A1 SUBSTITUTED PYRIDINES, PROCESS FOR PRODUCING THEM AND THEIR USE AS PESTICIDES AND FUNGICIDES HOECHST SCHERING AGREVO GMBH (DE) 1995-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378399-A1 NOVEL VASCULAR LEAKAGEAGE INHIBITOR PGF, VEGFA, VCAM1 IDO1 4844/4885AGXT 3473/4885CYP3A4 3782/4885
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 IDO1 3029/4885AGXT 131/4885CYP3A4 3344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.